The Teva Pharmaceuticals subsidiary will have exclusive rights to distribute NantHealth's comprehensive molecular cancer test in Israel.
The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
Lunatus will have exclusive rights to distribute GPS Cancer to physicians in the UAE, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon.
Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its Harmony NIPT.
In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.
After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.
Canada begins its search for a chief government science advisor, Nature News reports.
A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.